Before Invest
AMGEN INC logo

AMGEN INC

AMGN
Biological Products No Disgnostic Substances
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Unlock 14 years
Statement
Period
Annual Quarterly
Order
Format
% Change
Rows
USD ($)
$ in Millions, shares in Millions		LTMDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011Dec 31, 2010Dec 31, 2009
Revenues:
                  
Product sales
-
-
-
-
Total revenues
38,095
36,751
33,424
28,190
Other revenues
-
-
-
-
Operating expenses:
                  
Cost of sales
11,613
12,037
12,858
8,451
Cost of sales (excludes amortization of certain acquired intangible assets presented separately)
-
-
-
-
Research and development
7,629
7,272
5,964
4,784
Acquired in-process research and development
-
-
-
0
Selling, general and administrative
7,019
7,050
7,096
6,179
Amortization of certain acquired intangible assets
-
-
-
-
Other
408
1,312
248
879
Total operating expenses
26,669
27,671
26,166
20,293
Operating income
11,426
9,080
7,258
7,897
Other income (expense):
                  
Interest expense, net
2,668
2,755
3,155
2,875
Other income, net
1,529
2,651
506
2,833
Total income before income taxes
10,287
8,976
4,609
7,855
Provision for income taxes
1,544
1,265
519
1,138
Net income
$ 8,743
$ 7,711
$ 4,090
$ 6,717
Earnings per share:
                  
Basic (in usd per share)
$ 16.22
$ 14.33
$ 7.62
$ 12.56
Diluted (in usd per share)
$ 16.1
$ 14.23
$ 7.56
$ 12.49
Weighted-average shares used in the calculation of earnings per share:
                  
Basic (in shares)
540
538
537
535
Diluted (in shares)
544
542
541
538